EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NMR screening of low molecular weight inhibitors targeting the papain‐like protease ( PLPro ) of SARS ‐ CoV ‐2

Dennis J Pyper, Sridhar Sreeramulu, Benjamin T Lanham, Elizabeth M Engle, David Fushman, Harald Schwalbe iD

FEBS Open Bio · 2025

DOI: 10.1002/2211-5463.70082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Open Bio, 2025. Verfasst von Dennis J Pyper und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Organic Chemistry and Chemical Biology, Center for Biomolecular Magnetic Resonance (BMRZ), Goethe-University Frankfurt/M, Germany. Hauptthemen laut MEDLINE: SARS-CoV-2, Coronavirus Papain-Like Proteases, Antiviral Agents, Protease Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Maryland, Deutsche Forschungsgemeinschaft, Jenny T. Sih Endowed Memorial Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Papain‐like protease (PLPro) from SARS‐CoV‐2 plays an important role in the cleavage of the polyproteins Pp1a and Pp1ab as well as in the suppression of the immune response by deISG15ylation. Considerable effort is therefore devoted to developing low molecular weight inhibitors as starting points for antiviral drugs. Here, we present the results of an NMR screening study of PLPro for binding to the DSI‐poised fragment library containing 607 compounds. Based on saturation‐transfer difference (STD)‐ and WaterLOGSY‐NMR experiments, we identified 86 binding compounds. We prioritized five candidates for further in‐depth analysis. For three of those, we determined dissociation constants and two distinct binding sites on PLPro. These compounds could serve as a basis for future drug design studies in medicinal chemistry.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Coronavirus Papain-Like ProteasesAntiviral AgentsProtease InhibitorsCoronavirus 3C ProteasesHumansMagnetic Resonance SpectroscopyMolecular WeightCOVID-19Binding SitesDrug Evaluation, PreclinicalCOVID-19 Drug TreatmentProtein Binding

Stichwörter der Autor:innen

NMR spectroscopyNsp3dSARS‐CoV‐2coronavirusfragment‐based NMR screeningpapain‐like protease PLPro

Substanzen

Coronavirus Papain-Like Proteasespapain-like protease, SARS-CoV-2Antiviral AgentsProtease InhibitorsCoronavirus 3C Proteases

Autor:innen und Institutionen

  • Institute of Organic Chemistry and Chemical Biology, Center for Biomolecular Magnetic Resonance (BMRZ), Goethe-University Frankfurt/M, Germany.
  • Center for Biomolecular Structure and Organization, Department of Chemistry and Biochemistry, University of Maryland, College Park, MD, USA.

ORCID-Profile: Harald Schwalbe

Förderung

  • University of Maryland
  • Deutsche Forschungsgemeinschaft
  • Jenny T. Sih Endowed Memorial Fellowship
  • European Union's Horizon 2020 research and innovation program
  • Hessisches Ministerium für Wissenschaft und Kunst
  • Maryland Summer Scholarship

Zitieren

APA

Pyper, D. J., Sreeramulu, S., Lanham, B. T., Engle, E. M., Fushman, D., & Schwalbe, H. (2025). NMR screening of low molecular weight inhibitors targeting the papain‐like protease ( PLPro ) of SARS ‐ CoV ‐2. FEBS Open Bio. https://doi.org/10.1002/2211-5463.70082

Vancouver

Pyper DJ, Sreeramulu S, Lanham BT, Engle EM, Fushman D, Schwalbe H. NMR screening of low molecular weight inhibitors targeting the papain‐like protease ( PLPro ) of SARS ‐ CoV ‐2. FEBS Open Bio. 2025. doi:10.1002/2211-5463.70082

BibTeX
@article{Pyper2025,
  author = {Pyper, Dennis J and Sreeramulu, Sridhar and Lanham, Benjamin T and Engle, Elizabeth M and Fushman, David and Schwalbe, Harald},
  title = {NMR screening of low molecular weight inhibitors targeting the papain‐like protease ( PLPro ) of SARS ‐ CoV ‐2},
  journal = {FEBS Open Bio},
  year = {2025},
  doi = {10.1002/2211-5463.70082}
}
Kostenlos starten →